Covid-19 Antibody Race Heats Up
(Bloomberg) -- The race to find successful antibody treatments against Covid-19 is heating up as GlaxoSmithKline Plc and Vir Biotechnology Inc. start human trials to evaluate a potential drug that could be available as soon as the first half of next year.
The therapy is advancing directly to the middle and final stages of clinical tests with a study that began last week, the companies said in a statement Monday. The trials will involve 1,300 high-risk patients from across the globe and focus on preventing hospitalization for people with early or mild coronavirus symptoms, with initial results possible before year-end.
Glaxo and Vir are among a number of drugmakers seeking to fight, or even prevent, Covid-19 with monoclonal antibodies, which aim to mimic the body's natural immune response. Such treatments could provide a short-term solution before a vaccine becomes available, and may also be necessary for older or more vulnerable people who don't respond as well to a shot.
AstraZeneca Plc also said last week it had started human trials for a combination of two antibodies, while early data from a pair of antibodies being tested by Regeneron Pharmaceuticals Inc. are due in September. Eli Lilly & Co. started final-stage trials for its drug in U.S. nursing homes this month.
A successful treatment could bypass the need for the body to produce its own antibodies, which is especially important in the absence of an effective vaccine, said Hal Barron, Glaxo's head of research. The companies are also planning further studies looking at preventing infection and treating more seriously ill hospitalized patients.
“A vaccine is incredibly important for the impact it can have at scale,” Barron said in an interview. “But we do believe this monoclonal antibody in particular is unique and that the class in general will potentially play a very important role in this pandemic.”
Glaxo and Vir, which signed a $250 million Covid-19 pact in April, are also looking at potential vaccines for the disease, as well as treatments and shots for other coronaviruses. A mid-stage trial for a second antibody treatment that could also act as a prophylactic T cell vaccine is due to start later this year.
“The need for these antibodies is likely to be so large that no one company will be able to provide it all,” George Scangos, Vir's chief executive officer, said in an interview.
©2020 Bloomberg L.P.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.